Barely Significant
← all excerpts

Contemporary Management of Dyslipidemia.

Drugs · 2022 · PMC8931779 · PMID 35303294

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

nominally significantp = 0.06so close (0.05 < p ≤ 0.1)
showed a trendno p-value reported
Post hoc analysis of the ACCORD trial, which included patients with the highest tertile of triglycerides (≥204 mg/dL), showed a trend toward benefit from fenofibrate therapy, although this finding was nominally significant (primary outcome 12.4% in the fenofibrate group vs 17.6% in the placebo arm, p = 0.06) [ 119 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.